Seres Therapeutics, Inc. (MCRB)
After hours:
| Previous close | 6.42 |
| Open | 6.46 |
| Bid | 6.16 x 3200 |
| Ask | 6.61 x 1800 |
| Day's range | 6.11 - 6.55 |
| 52-week range | 2.50 - 11.69 |
| Volume | |
| Avg. volume | 1,116,928 |
| Market cap | 768.006M |
| Beta (5Y monthly) | 3.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings date | 08 Nov 2022 - 14 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.14 |
- Business Wire
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
CAMBRIDGE, Mass., September 08, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance Congress being held on September 7-8, 2022 in National Harbor, Maryland. Dr. Henn will present at 12:00 p.m. ET today a presentation entitled: "Microbiome Therapeutics to Potentially Transform the Management of Antimicrobial Resistant Infectio
- Business Wire
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
CAMBRIDGE, Mass., September 07, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI). SER-109 is an entirely new treatment modality that shows promise to improve the current standard of care for rCDI.
- Simply Wall St.
Calculating The Intrinsic Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
In this article we are going to estimate the intrinsic value of Seres Therapeutics, Inc. ( NASDAQ:MCRB ) by taking the...
